Sio Capital Management’s Orchestra BioMed OBIO Stock Holding History

Sio Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-250,000	Closed	-$2.5M	–	51
2022 Q4	$2.5M	Hold	250,000	–	–	0.92%	21
2022 Q3	$2.48M	Hold	250,000	–	–	0.79%	21
2022 Q2	$2.49M	Hold	250,000	–	–	0.94%	30
2022 Q1	$2.48M	Hold	250,000	–	–	0.82%	30
2021 Q4	$2.52M	Hold	250,000	–	–	0.76%	35
2021 Q3	$2.47M	Hold	250,000	–	–	0.79%	38
2021 Q2	$2.55M	Hold	250,000	–	–	0.63%	48
2021 Q1	$2.8M	Hold	250,000	–	–	0.57%	54
2020 Q4	$3.2M	Hold	250,000	–	–	0.66%	52
2020 Q3	$2.75M	Buy	+250,000	New	+$2.81M	0.54%	50

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SFG

SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Sio Capital Management's OBIO Position: Q1 2023 in Review

Sio Capital Management sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 250,000 shares — an estimated $2.5M sold.

Sio Capital Management first reported a position in OBIO in Q3 2020 and held it in 10 quarters. The position peaked at $3.2M in Q4 2020. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

Sio Capital Management reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
Sio Capital Management sold 250,000 Orchestra BioMed shares in Q1 2023, an estimated $2.5M.
Sio Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 10 quarters.
Sio Capital Management's Orchestra BioMed position peaked at $3.2M in Q4 2020.
22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on Sio Capital Management's 13F filing for Q1 2023, filed 12 May 2023.